May 6, 2021
Hospira recalls one lot each of 0.5% Bupivacaine and 1% Lidocaine because of mislabeling
Editor's Note
Hospira Inc, a Pfizer company, announced May 4 that it is recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCL Injection, USP 30 mL because of mislabeling.
A portion of each lot was incorrectly labeled as the other product. The issue was identified by a customer.
Use of the impacted products could cause adverse events of moderate to high severity.
Free Daily News
- Infection control guidelines focus on regional anesthesia, pain management
- Study links high surgeon stress, positive patient outcomes
- Researchers recommend extending colonoscopy screening interval for low-risk patients
- New wrong-site surgery prevention toolkit seeing traction in ASCs
- Podcast episode discusses the anesthesia provider shortage in ASCs
- Study explores use of antibiotics as alternative to pediatric appendectomy
- Medical device shortages present pediatric patient challenges, FDA warns
- Expansive study highlights GLP-1 risks, potential beyond weight loss, diabetes treatment
- HHS report highlights cost, access, quality concerns with private equity in healthcare
- Study: Racial, gender disparities persist in bariatric surgery
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement